trending Market Intelligence /marketintelligence/en/news-insights/trending/iqtj_hwnhzqemsuj7lemfa2 content esgSubNav
In This List

Profound Medical's device to treat uterine tumors approved by Chinese regulator

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Profound Medical's device to treat uterine tumors approved by Chinese regulator

Profound Medical Corp. said the China Food and Drug Administration approved its device Sonalleve for the noninvasive treatment of uterine fibroids.

Uterine fibroids are the most common noncancerous tumors of the female reproductive tract in women, according to the company.

The Canadian device-maker said the product enables more precise and incision-free removal of diseased tissue.

Profound Medical acquired the Sonalleve MR-HIFU business from Royal Philips in 2017.